New report says accelerated approval pathway for early-phase clinical trials could save Poland’s health system millions while attracting high-value biomedical investment
Poland could strengthen its position as one of Europe’s leading clinical trial hubs if it introduces a fast-track approval system for early-stage studies, according to a new economic analysis commissioned by major organisations representing the country’s clinical research sector.
The report, “Fast-track for trials: Is it worth it?”, prepared by the Polish Network of Economics (PLSE), argues that shortening registration procedures for phase I and II clinical trials could generate substantial savings for the healthcare system while boosting innovation, employment and scientific capacity.
“Poland has a real opportunity to use its clinical research potential to strengthen its position in the European and global competition for innovation investment,” Michał Byliniak, director general of Infarma, the Polish association of innovative pharmaceutical companies, told Euractiv.
“The greatest leverage lies in shortening trial start-up times and investing in clinical research data and infrastructure,” he added.
